Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus chemotherapy vs bevacizumab plus chemotherapy in treatment-naive metastatic colorectal cancer
jRCT2071250106Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of PF-08634404 in metastatic colon cancer (mCRC) (2 arms), sponsored by Pfizer. Started Jan 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2071250106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250106.